Lepu Biopharma Co., Ltd. (HKG:2157)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.390
+0.220 (5.28%)
Mar 6, 2026, 4:08 PM HKT
Market Cap7.92B +67.2%
Revenue (ttm)767.54M +241.5%
Net Income-194.17M
EPS-0.11
Shares Out1.80B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,796,000
Average Volume5,365,025
Open4.250
Previous Close4.170
Day's Range4.080 - 4.430
52-Week Range3.050 - 10.500
Beta-0.24
RSI43.04
Earnings DateMar 27, 2026

About Lepu Biopharma

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of first-in class and best-in-class drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 546
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2157
Full Company Profile

Financial Performance

In 2024, Lepu Biopharma's revenue was 367.79 million, an increase of 63.21% compared to the previous year's 225.35 million. Losses were -411.38 million, 1761.8% more than in 2023.

Financial numbers in CNY Financial Statements